FHFiras Hamood

Firas Hamood

*This is an algorithmically generated author record based on publicly available information.

Firas Hamood has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemical proteomics decrypts the kinases that shape the dynamic human phosphoproteome

    by Florian P. Bayer, Julian Müller, Nicole Kabella, Miriam Abele, Yun-Chien Chang, Leonardo Daniel Estrada Duenas, Cecilia Jensen, Firas Hamood, Chien-Yun Lee, Annika Schneider, et al.

    Mass-spectrometry-based phosphoproteomics enables the analysis of thousands of protein phosphorylation events across the human proteome. However, there is a lack of scalable, hypothesis-free, and statistically sound approaches for discovering, evaluating, and falsifying kinase::substrate relationships (KSRs). Here, we developed a new concept termed potency-coherence analysis. By measuring and integrating 17 million peptidoform-specific dose-response curves for 133 kinase inhibitors with known targets and affinities, we could critically re-evaluate published KSRs and discover thousands of potency-coherent and motif-plausible new KSRs for 96 human kinases. Application of these high-confidence KSRs enabled the estimation of kinase and signaling pathway activities in cancer patient biopsies. This unified and extendable framework has been implemented in ProteomicsDB to aid researchers in understanding the human phosphoproteome in health and disease.


  • Open Access

    ProSIMSIt: The Best of Both Worlds in Data-Driven Rescoring and Identification Transfer

    by Firas Hamood, Wassim Gabriel, Pia Pfeiffer, Bernhard Kuster, Mathias Wilhelm, Matthew The

    Multibatch isobaric labeling experiments are frequently applied for clinical and pharmaceutical studies of large sample cohorts. To tackle the critical issue of missing values in such studies, we introduce the ProSIMSIt pipeline. It combines the advantages of tandem mass spectrum clustering via SIMSI-Transfer and data-driven rescoring via Prosit and Oktoberfest. We demonstrate that these two tools are complementary and mutually beneficial. On large-scale cancer cohort data, ProSIMSIt increased the number of peptide spectrum matches (PSMs) by 40% on both global and phosphoproteome data sets. Furthermore, on data from proteome-wide drug-response profiling of post-translational modifications (decryptM), our pipeline substantially increased drug-PTM relations and revealed previously unseen downstream effects of drug target inhibition. ProSIMSIt is available as an open-source Python package with a simple command line interface that allows easy application to MaxQuant result files.


  • Open Access

    Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

    by Stefanie Höfer, Larissa Frasch, Kerstin Putzker, Joe Lewis, Amirhossein Sakhteman, Matthew The, Florian P. Bayer, Julian Müller, Firas Hamood, Bernhard Kuster

    The DNA-damaging agent gemcitabine (GEM) is a first-line treatment for pancreatic cancer but chemoresistance is frequently observed. Several clinical trials investigate the efficacy of GEM in combination with targeted drugs including kinase inhibitors but the experimental evidence for such rational is often unclear. Here, we phenotypically screened 13 human pancreatic adenocarcinoma (PDAC) cell lines against GEM in combination with 140 clinical kinase inhibitors and observed strong synergy for the ATR inhibitor Elimusertib in most cell lines. Dose-dependent phosphoproteome profiling of four ATR inhibitors following DNA damage induction by GEM revealed a strong block of the DNA damage response pathway including phosphorylated pS468 of CHEK1 as the underlying mechanism of drug synergy. The current work provides a strong rationale for why the combination of GEM and ATR inhibition may be useful for the treatment of PDAC patients and constitutes a rich phenotypic and molecular resource for further investigating effective drug combinations.


  • Open Access

    Oktoberfest: Open‐source spectral library generation and rescoring pipeline based on Prosit

    by Mario Picciani, Wassim Gabriel, Victor‐George Giurcoiu, Omar Shouman, Firas Hamood, Ludwig Lautenbacher, Cecilia Bang Jensen, Julian Müller, Mostafa Kalhor, Armin Soleymaniniya, et al.

    Machine learning (ML) and deep learning (DL) models for peptide property prediction such as Prosit have enabled the creation of high quality in silico reference libraries. These libraries are used in various applications, ranging from data‐independent acquisition (DIA) data analysis to data‐driven rescoring of search engine results. Here, we present Oktoberfest, an open source Python package of our spectral library generation and rescoring pipeline originally only available online via ProteomicsDB. Oktoberfest is largely search engine agnostic and provides access to online peptide property predictions, promoting the adoption of state‐of‐the‐art ML/DL models in proteomics analysis pipelines. We demonstrate its ability to reproduce and even improve our results from previously published rescoring analyses on two distinct use cases. Oktoberfest is freely available on GitHub (https://github.com/wilhelm‐lab/oktoberfest) and can easily be installed locally through the cross‐platform PyPI Python package.


  • Top Cited Papers

    Decrypting drug actions and protein modifications by dose- and time-resolved proteomics

    by Jana Zecha, Florian P. Bayer, Svenja Wiechmann, Julia Woortman, Nicola Berner, Julian Müller, Annika Schneider, Karl Kramer, Mar Abril-Gil, Thomas Hopf, et al.

    Although most cancer drugs modulate the activities of cellular pathways by changing posttranslational modifications (PTMs), little is known regarding the extent and the time- and dose-response characteristics of drug-regulated PTMs. In this work, we introduce a proteomic assay called decryptM that quantifies drug-PTM modulation for thousands of PTMs in cells to shed light on target engagement and drug mechanism of action. Examples range from detecting DNA damage by chemotherapeutics, to identifying drug-specific PTM signatures of kinase inhibitors, to demonstrating that rituximab kills CD20-positive B cells by overactivating B cell receptor signaling. DecryptM profiling of 31 cancer drugs in 13 cell lines demonstrates the broad applicability of the approach. The resulting 1.8 million dose-response curves are provided as an interactive molecular resource in ProteomicsDB.


  • Open Access

    Enhancing treatment recommendations in precision oncology with proteomics and phosphoproteomics data

    by Cecilia Bang Jensen, Annika Schneider, Matthew The, Amirhossein Sakhteman, Julia Woortman, Christina Göbel, Firas Hamood, Moritz Resch, Florian Bayer, Chien-Yun Lee, et al.

    While DNA and RNA sequencing are increasingly applied in precision oncology, the therapeutically important (phospho)proteome is rarely included. We implemented a clinical proteomics workflow into two existing molecular tumour board programs. Here, we present the semi-automated analysis of (phospho)proteomic data allowing therapeutic suggestion within a turnaround time of two weeks. Currently, the cohort consists of >500 individual patient samples from various entities, predominantly sarcomas. 2 batches/week (16 patients) are processed with a multiplexing strategy (TMT-11), allowing high throughput and high (phospho)proteome coverage. For most patients, expression data of >8,000 proteins and >20,000 phospho-sites are measured. The quantified proteins and phospho-peptides are normalised within and across batches. A PCA analysis confirmed that most batch effects were successfully removed. The normalised data establishes a background cohort used in calculating z-scores for each protein/p-site. Single patient proteomes are then analysed at a protein abundance level and phospho activity level using z-scores to find aberrant activity. A strategy integrating different levels of signalling eg. substrate phosphorylation, using manually curated annotations scores 39 cancer-related signalling pathways and 4 treatment-related biomarker groups for relevance. Our results show that (phospho)proteomics can support genomic findings and provide new treatment suggestions.